[Edaily Starin Gim Ga Yeong Reporter] The Netflix series “Donggung” has ranked second among global non-English series. Photo: NetflixAccording to Netflix’s official site, Tudum, on the 29th, “Donggung” recorded 8.1 million views (viewing time divided by the show’s total runtime) from the 20th to the 26th, securing the No. 2 spot in Netflix’s global non-English TV shows category. It made it into the top 10 in 69 countries, including Brazil, Colombia, Peru, the Czech Republic, Spain, France, Italy, Ukraine, and Portugal. “Donggung” is a Netflix series that follows Gu Cheon (Nam Joo-hyuk), who possesses the ability to traverse the spirit world, and Saeng-gang (Noh Yoon-seo), a palace maid harboring a secret, as they are summoned by the king (Jo Seung-woo) to uncover the curse that haunts the East Palace. The top spot was claimed by the French production “GIGN: Elite Force,” which recorded 10.1 million views. SBS’s Friday-Saturday drama “Director Kim” took third place with 7.3 million views. “Director Kim” is a revenge action drama about an ordinary father who becomes a dangerous man to fight and reclaim his only daughter. It garnered attention for its star-studded cast, including actors So Ji-sub, Choi Dae-hoon, Yoon Kyung-ho, and Joo Sang-wook. Building on the success of its predecessor, “Brave New World,” “Director Kim” surged in popularity, claiming the No. 1 spot globally in Netflix’s non-English TV shows category for three consecutive weeks. According to Netflix’s official site, Tudum, “Director Kim” ranked No. 1 globally among non-English TV shows, recording △10.5 million views from the 29th of last month to the 5th of this month, △9.1 million views from the 6th to the 12th, and △8.2 million views from the 13th to the 19th.
Business leaders from South Korea and Brazil have agreed to expand cooperation across a wide range of strategic industries, from critical mineral supply chains to artificial intelligence (AI), biotech…
Ingenia Therapeutics (Ingenia), an innovative antibody drug developer set to list on KOSDAQ, has brought a treatment for chronic kidney disease (CKD) to the negotiating table with a global big pharma …
Bae Yo-han, Head of Clinical Development at KANGSTEM BIOTECH CO., LTD., is presenting at a briefing on the results of the Oscar Phase 2a clinical trial held at the FKI Tower in Yeouido, Seoul, on the …